Alwaysraise LLC

Alwaysraise LLC is a life sciences advisory and investment firm based in San Francisco, California, that provides specialized financial advisory services, including mergers, acquisitions, and equity financing. The organization primarily supports both early-stage and established biotechnology, oncology, and therapeutics companies by guiding them through complex financial transactions, capital fundraisings, and strategic corporate sales. Alwaysraise generates revenue through advisory fees and has advised industry clients such as Oncodisc, Inc., acting as the exclusive financial advisor during its sale to the PAVmed Digital Health subsidiary Veris Health Inc. Additionally, the firm leverages sector experience from its leadership, who previously served as the interim Chief Financial Officer for Zap Surgical and successfully completed an $81 million equity financing round for the medical device enterprise. Alwaysraise LLC was officially established in 2020 and was founded by Gabriel Morris.

High-Level Overview

Alwaysraise LLC is a San Francisco-based advisory and investment firm specializing in life sciences, particularly medical devices, biopharma, digital health, and biopharmaceuticals. Its mission centers on addressing unmet needs in medicine by facilitating private placements, fundraising, mergers & acquisitions (M&A), IPOs, and corporate development transactions like licensing and divestitures.[1][2][4][6] The firm's investment philosophy emphasizes a "Liftoff" process for optimal fundraising strategies, deep industry analysis for expansion, and tight integration with clients' clinical milestones to drive exits and growth.[2][3] Key sectors include global biopharmaceuticals, medical technology, oncology care platforms, and precision medicine, with a strong impact on the startup ecosystem through exclusive advisory roles in high-stakes deals, such as Oncodisc, Inc.'s sale to PAVmed's Veris Health.[3]

Origin Story

Alwaysraise LLC was founded by Gabriel Morris, who serves as its managing partner and brings a background from Goldman Sachs and Columbia University. Morris also holds the role of Chief Financial Officer at Immix Biopharma, Inc., underscoring his deep ties to life sciences leadership.[5] The firm emerged to tackle "the largest problems and unmet needs in medicine," evolving from a focus on investment banking services into a comprehensive advisory platform for medtech, biotech, and digital health startups.[1][4][5][6] A pivotal early moment includes acting as exclusive financial advisor for Oncodisc, Inc., a remote oncology care platform, earning praise from its CEO for transformative financing and M&A support.[3]

Core Differentiators

• Unique Investment Model: Employs a structured "Liftoff" methodology for private placements and fundraising, combining comprehensive outreach, deal structuring, and efficient closings with global clinical milestone alignment.[2]
• M&A and Exit Expertise: Specializes in optimal strategies for sales, divestitures, IPOs, spin-offs, and expansions, including deep-dive industry analysis to identify partners and growth sectors.[2][3]
• Network Strength and Track Record: Led by Gabriel Morris with Wall Street credentials; proven in transactions like Oncodisc's acquisition, positioning clients "on the pathway to success" via exclusive advisory.[3][5]
• Operating Support in Life Sciences: Focuses on biopharma/medtech corporate development, licensing (in/out), business model transformations, and market path optimization for medical devices, biopharma, and digital health.[2][4][6]

Role in the Broader Tech Landscape

Alwaysraise rides the wave of accelerating life sciences innovation, where medtech and biopharma startups face funding crunches amid rising clinical costs and demand for breakthroughs in oncology, precision medicine, and remote care. Timing is critical as global biopharma licensing and M&A surge post-pandemic, fueled by market forces like aging populations, AI-driven drug discovery, and investor appetite for scalable digital health exits.[2][3][6] The firm influences the ecosystem by bridging startups to IPOs/acquisitions, expanding opportunity pipelines, and providing rocket-fuel expertise that de-risks high-stakes clinical paths—evident in deals like Oncodisc's pivot to Veris Health.[3]

Quick Take & Future Outlook

Alwaysraise is poised to capitalize on biopharma consolidation and digital health scalability, potentially scaling its portfolio through more IPOs and cross-border licensing as AI and remote monitoring trends mature. Evolving regulatory tailwinds for medtech and venture interest in derisked assets will shape its trajectory, amplifying influence via Morris's board roles and C-suite networks. As medicine's "needle-mover," expect Alwaysraise to orchestrate more transformative exits, solidifying its role in fueling the next wave of life sciences unicorns.[2][4][5][6]